Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03491267 · ClinicalTrials.gov registry record · Early Phase 1
Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT03491267: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT03491267 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03491267, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The investigators have extensive evidence in mouse that wounding leads to the generation of new hair follicles in the skin. This can be an important new therapy for patients with scarring, but especially those with alopecia. The question is whether gentle wounding in human subjects can cause the generation of a new hair follicle. The plan is to first carefully map a small area of the scalp without hair follicles. Investigators will then try various modalities of gentle wounding (including fractionated Carbon Dioxide (CO2) laser, mild curetting) of the surface epithelium in the presence and absence of FDA approved topical medications (including retinoids). Investigators will then prospectively monitor the area for hair growth both by noninvasive visual monitoring (including photographs and dermoscopy) and biopsies. The outcomes of this study hopefully will allow new therapies for especially scarring alopecia conditions where hair follicles are completely lost and there are no current therapies.
Interventions
- DEVICE Laser
- DEVICE Sham treatment
- DRUG Sham treatment
- DRUG Retinoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2024-11-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03491267
The ClinicalTrials.gov registry entry for NCT03491267 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laser is the first listed.
NCT03491267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03491267 about?
NCT03491267 is a clinical study titled "Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis". The investigators have extensive evidence in mouse that wounding leads to the generation of new hair follicles in the skin. This can be an important new therapy for patients with scarring, but especially those with alopecia. The question is whether gentle wounding in human subjects can cause the ge...
What is the current status of trial NCT03491267?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2018-01-01. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT03491267?
The interventions under investigation include: Laser (DEVICE), Sham treatment (DEVICE), Sham treatment (DRUG), Retinoic acid (DRUG).
Who is sponsoring clinical trial NCT03491267?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.